Despite current stock market volatility, equities may still offer solid returns over the next five years, particularly in the healthcare sector. Two companies stand out: Moderna (MRNA) and Abivax (ABVX). Moderna’s mRNA platform, which has already proven effective with its COVID-19 vaccine, is advancing with promising candidates like its flu vaccine and a personalized cancer vaccine, mRNA-4157, which has shown significant efficacy in clinical trials. The stock has surged approximately 73% this year, and while risks remain, particularly in clinical and regulatory areas, it may continue to appeal to risk-tolerant investors.
Abivax, a French biotech firm, is positioning itself in the ulcerative colitis market with its innovative candidate, obefazimod. Unlike traditional immunosuppressants, obefazimod shows potential for effective treatment without serious side effects. Positive outcomes from ongoing trials could significantly enhance its market position and sales prospects, making it a compelling option for investors willing to embrace higher risk.
In summary, both Moderna and Abivax present intriguing opportunities for growth in a volatile market, particularly for those focused on the healthcare sector.
Source: fool.com